Erectile dysfunction (ED) is a topic of considerable importance to men’s health. In men with cardiovascular disease and diabetes mellitus especially, ED is increasingly being recognized as a comorbid condition. ED is a treatable condition, but some treatment options—sex therapy, implants, vacuum devices, intracavernosal injections, and herbal medications and creams—could be time consuming, painful, awkward, or of questionable efficacy. The advent of oral phosphodiesterase 5 (PDE5) inhibitors has revolutionized the treatment of men with ED.
Clinicians now have the option of prescribing one of three PDE5 inhibitors – sildenafil citrate (Viagra1), tadalafil (Cialis1), or vardenafil HCl (Levitra1). As with any therapy for any disorder, treatment success may be influenced greatly by such diverse factors as dosing instructions, timing of desired effect following dosing, food and medication interactions, and knowledge of adverse events. For the clinician, an awareness of pharmacodynamic and pharmacokinetic properties of amedication can facilitate patient education, and appropriate follow-up provided by an informed clinician can detect obstacles to successful treatment.
This report is designed to provide primary care clinicians with answers to frequently asked questions about tadalafil. The report is provided in two parts. The first is frequently asked questions about optimizing tadalafil therapy in treating men with ED. The second reviews frequently asked questions about howthe safety and tolerability of tadalafil have been established. The intent is to apply recent scientific research to ‘‘the bedside’’ or clinic in a practical fashion. The review is framed in a question and answer style so that busy clinicians can quickly and easily find the questions for which they have the most interest. The information presented is based on data from the scientific literature, product labeling, and the clinical insights of the authors.
Because men’s health is a global issue, this report is written from a global perspective, but information regarding prescribing is based on the United States Package Insert (‘‘label’’). Physicians in other countries should note that label language and doses might vary in different countries and regions. This is a normal consequence of different regulatory agencies viewing a dataset pertaining to a particular pharmacological agent in different ways.
Clinicians now have the option of prescribing one of three PDE5 inhibitors – sildenafil citrate (Viagra1), tadalafil (Cialis1), or vardenafil HCl (Levitra1). As with any therapy for any disorder, treatment success may be influenced greatly by such diverse factors as dosing instructions, timing of desired effect following dosing, food and medication interactions, and knowledge of adverse events. For the clinician, an awareness of pharmacodynamic and pharmacokinetic properties of amedication can facilitate patient education, and appropriate follow-up provided by an informed clinician can detect obstacles to successful treatment.
This report is designed to provide primary care clinicians with answers to frequently asked questions about tadalafil. The report is provided in two parts. The first is frequently asked questions about optimizing tadalafil therapy in treating men with ED. The second reviews frequently asked questions about howthe safety and tolerability of tadalafil have been established. The intent is to apply recent scientific research to ‘‘the bedside’’ or clinic in a practical fashion. The review is framed in a question and answer style so that busy clinicians can quickly and easily find the questions for which they have the most interest. The information presented is based on data from the scientific literature, product labeling, and the clinical insights of the authors.
Because men’s health is a global issue, this report is written from a global perspective, but information regarding prescribing is based on the United States Package Insert (‘‘label’’). Physicians in other countries should note that label language and doses might vary in different countries and regions. This is a normal consequence of different regulatory agencies viewing a dataset pertaining to a particular pharmacological agent in different ways.
No comments:
Post a Comment